Subscribe to RSS
DOI: 10.1055/s-2006-945668
LONG-TERM ATOMOXETINE ADMINISTRATION FOR YOUNG CHILDREN WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER
Objectives: The purpose of this presentation is to report on the efficacy and tolerability of long-term atomoxetine treatment among young children with attentiondeficit/ hyperactivity disorder (ADHD).
Methods: Data from 6- and 7-year old children (n=192) enrolled in similarly designed clinical trials that met DSM-IV criteria for ADHD were pooled. The children had a minimum of 12 months of atomoxetine treatment and 97 (51%) receive treatment for >24 months. The mean modal dose (SD) of atomoxetine was 1.55mg/kg/day (0.32). The primary efficacy outcome measure was the mean change from baseline to endpoint in the ADHD Rating Scale-IV (ADHD RS). The Conners' Parent Rating Scale-Revised: Short Form (CPRS-R:S) was a secondary efficacy measure.
Results: Significant mean treatment effects from baseline to endpoint for ADHD RS and CPRS-R:S scores were observed (P<.001). The effectiveness of atomoxetine treatment for children was maintained over long-term treatment as demonstrated by ADHD RS total and T-scores. Adverse events were clinically minor and transient, and only 1.6% of children discontinued due to adverse events. There were no clinically meaningful changes in laboratory tests. Also, further follow-up and analyses are ongoing.
Conclusion: Long-term atomoxetine treatment appears to be well-tolerated and effective in young children with ADHD.